Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) has confirmed two responses of the NY-ESO SPEAR T-cells while another one is yet to be confirmed. However, there was one stable disease in the first four patients dosed with the therapy in a second solid tumor: myxoid/ round cell liposarcoma (MRCLS). Results have it that a majority of patients tolerated treatment well. This is only a plus for GlaxoSmithKline plc, which was in charge of licensing the right to research, develop, and commercialize NY‑ESO SPEAR T-cell therapy program.
The responses are a confirmation that NY-ESO SPEAR T-cells can treat a wide range of tumors
Adaptimmune’s Chief Medical Officer, Rafael Amado is excited about the initial responses of NY-ESO SPEAR T-cells. It exhibits its potential in treating a broad range of tumors and especially those known to be unresponsive to current immunotherapies.
Amado writes, “As we expect data from our other trials with our wholly owned assets throughout 2018, these results in a second solid tumor strengthen our conviction that our pipeline of unique TCRs will be capable of addressing multiple solid tumors.”
Estimates have it that close to 2000 patients in the United States and Europe are living with MRCLS, considered to be soft tissue sarcomas alongside synovial sarcoma. Its symptoms include the proliferation of adipocyte (fat cell) precursors called lipoblasts. It also exhibits a unique metastatic pattern in the proximal areas of the boundaries. On the other hand, Synovial sarcoma is characterized by a different chromosomal translocation, which involves the X chromosome and chromosome 18.
Adaptimmune continues to make progress towards its ambition
Adaptimmune primary goal is to be a fully integrated cell therapy company. It has manufactured a number of batches for patients and apparently, all of them have achieved cell volumes in the range of NY-ESO. The company is also holding onto a healthy financial position in the delivery of SPEAR T-cell therapies
Other plans by the leader in T-cell therapy include executing an agreement with Cell and Gene Therapy (CGT) Catapult. The agreement will enable Adaptimmune own dedicated vector manufacturing space in the UK.